Open original FDA record ↗Recall record
- FDA identifier
- Z-1245-2015
- Company in FDA record
- Baxter Healthcare Corp.
- FDA classification date
- Mar 4, 2015
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Additional warning in the AMIA APD System labeling for patients vulnerable to unintended Increased Intraperitoneal Volume (IIPV), also known as overfill. The patients include neonates, infants, small children, and any patient with significant heart and/or lung disease.
Source facts
- Action
- Baxter sent IMPORTANT PRODUCT INFORMATION letters dated April 3, 2014 to all peritoneal dialysis healthcare providers of record. The letters advised healthcare providers of the potential to develop Increased Intraperitoneal Volume (IIPV) and instructed the healthcare providers to complete and return the attached Customer Reply Form. Healthcare providers with clinical questions can contact Baxter's Renal Division Clinical Helpline at 888-736-2543, option 2, 8:00 AM - 5:00 PM CT. Healthcare providers with general questions can contact The Center for One Baxter by telephone at 800-422-9837, Monday - Friday, 8:00 AM - 5:00 PM CT. Additionally, an IMPORTANT PRODUCT INFORMATION letters dated April 8, 2014 were sent to all peritoneal dialysis patients of record. The letters advised patients of the potential to develop Increased Intraperitoneal Volume (IIPV) and instructed the patients to complete and return the attached Home Patient Reply Form. Patients with questions about the letter can contact The Center for One Baxter by telephone at 800-422-9837, Monday - Friday, 8:00 AM - 5:00 PM CT.
- Initiated
- 2014-04-03
- Root cause
- Error in labeling
- Terminated
- 2017-07-21
- Distribution
- US: Nationwide in the states of (GA, MA, NC, NY, PA, WA)
- Recall number
- Z-1245-2015
- Recall status
- Terminated
- CDRH record ID
- 132475
- FDA classified
- 2015-03-04
- Recall event number
- 70194